Blood Thinners Reduced Stroke Risk in AFib Patients
A clinical trial found that treatment lowered adverse event rates in intermediate-risk AFib patients.
Updated on Oct. 2, 2026 in Heart Disease
Live Poll
If you are at intermediate risk for AFib-related stroke, would you start a blood thinner?
The SINGLE-AF clinical trial, presented in August 2026, demonstrated that blood thinners reduced the combined rate of stroke and cardiovascular death for intermediate-risk AFib patients. Researchers observed that treated individuals experienced significantly fewer ischemic strokes than those who remained untreated.
Why it matters
The study was conducted to resolve conflicting medical guidelines regarding whether intermediate-risk AFib patients benefit from blood thinner therapy. By providing randomized evidence, the results offer a clearer pathway for clinical decision-making in long-term cardiovascular care.
The trial of 1,803 patients reported a 69% reduction in combined adverse events and a major bleeding rate of 0.3% for the treated group compared to 0.5% in the untreated arm.
The players
European Society of Cardiology
This professional organization is a leading global authority that holds annual congresses to disseminate the latest cardiovascular research.
New England Journal of Medicine
This is a weekly peer-reviewed medical journal that publishes important research findings and clinical trial results in various medical fields.
Bristol Myers Squibb
This is a global biopharmaceutical company that develops and manufactures treatments for serious diseases, including the blood thinner Eliquis.
Centers for Disease Control and Prevention
This is the national public health agency of the United States that tracks disease prevalence and makes future health projections.
The details
The trial enrolled 1,803 patients across 18 hospitals in South Korea to compare the effectiveness of apixaban and rivaroxaban against no treatment. Using the CHA2DS2-VASc score to identify an intermediate stroke risk level, researchers found that the treated group saw only three ischemic strokes, whereas the untreated group recorded 10.
Timeline
Late August 2026: SINGLE-AF trial results presented at cardiology congress.
January 1, 2026: Medicare drug price negotiations took effect.
October 15, 2026: Medicare open enrollment period begins.
December 7, 2026: Medicare open enrollment period ends.
April 1, 2028: Earliest expected launch of generic Eliquis.
The Big Picture
This study aligns with the Inflation Reduction Act's Medicare drug-price negotiation provisions, which have lowered costs for medications like Eliquis and Xarelto.
Patients with intermediate-risk AFib may now consult their physicians regarding whether initiating blood thinner therapy is appropriate based on this new evidence. Those on Medicare might also find these specific medications more affordable following recent price negotiations.
The takeaway
The study underscores the necessity of clinical evidence in guiding treatment for patients at intermediate risk of stroke. Patients should discuss their individual risk scores and the potential benefits of anticoagulation therapy with a qualified medical professional.
Further reading
For more background on clinical management, visit the Heart Disease section.
Live Poll
If you are at intermediate risk for AFib-related stroke, would you start a blood thinner?
